ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/05/20

SOUTH SAN FRANCISCO, Calif. , May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) (the "Company" or " Portola ") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March...

Shares of Portola Pharmaceuticals (NASDAQ: PTLA) -- a biopharmaceutical company that focuses on the development of treatments for life-threatening blood disorders -- are up by a whopping 129% as of 12:11 p.m. EDT on Tuesday. The company's shares more than doubled following the news that Port...

"Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care," says Alexion (NASDAQ: ALXN ) CEO Ludwig Hantson. More news on: Alexion Pharmaceuticals, Inc., Portola Ph...

– Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent – – Conference call and webcast scheduled for today, May 5 , at 8:00 a.m. ET – Alexion Ph...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing the use of Alexion Pharmaceuticals' (NASDAQ: ALXN ) Ultomiris (ravulizumab) for patients with a body weight of at least 10 kg with atypical haemolytic uremic syndrome (aHUS) who are complement inhibi...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion  recommending marketing authorization for Alexion Pharmaceuticals' (NASDAQ: ALXN ) ULTOMIRIS (ravulizumab) for the treatment of patients with a body weight of 10 kg or above with atypical hemol...

– European Commission decision anticipated in June 2020 – – If approved, ULTOMIRIS has the potential to become the new standard of care in Europe for the treatment of atypical hemolytic uremic syndrome (aHUS) – – aHUS is an ultra-rare disease wh...

Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...

This past two months have been quite the emotional rollercoaster for investors. Since the benchmark S&P 500 hit an all-time record closing high on Feb. 19, 2020, we've witnessed: Beyond just breaking stock market records, we've also witnessed 22 million Americans lose their jobs in a four...